Figure.

Flow Diagram of Study Members

^aCommercial members, 25,243,5771; Medicare members, 37,345,7122

^bCommercial, premenopausal %, 25.91; Commercial, postmenopausal %, 9.61; Medicare %, 54.03

^cCommercial members, 16,275,3001; Medicare members, 17,179,028

^dCommercial %, 0.571; Medicare %, 0.704,5

^eCommercial members, 16,224,560; Medicare members, 17,036,896

^fCommercial %, 70.606; Medicare %, 66.807

^gCommercial %, 29.406; Medicare %, 33.207

^hCommercial %, 39.208; Medicare %, 39.208

ⁱCommercial %, 60.808; Medicare %, 60.808

^jCommercial %, 49.007; Medicare %, 30.307

^kCommercial %, 51.007; Medicare %, 69.707

^lCommercial, premenopausal %, 37.509; Commercial, postmenopausal %, 26.609; Medicare %, 26.609

^mCommercial, premenopausal %, 62.509; Commercial, postmenopausal %, 73.409; Medicare %, 73.409

1OptumInsight. Single payer database. 2014. Data on file at Baker Tilly, LLP.

2Centers for Medicare & Medicaid Services. On its 50th anniversary, more than 55 million Americans covered by Medicare. Press release. July 28, 2015. www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2015-Press-releases-items/2015-07-28.html.

3America's Health Insurance Plans Center for Policy and Research. Medicare Advantage demographics report. February 2015. https://ahip.org/wp-content/uploads/2015/02/MADemo_Report2015.pdf.

4OptumInsight. Medicare Outpatient Standard Analytic File. 2014. Data on file at Baker Tilly, LLP.

5Centers for Medicare & Medicaid Services. Physician and other supplier data CY 2014. www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Physician-and-Other-Supplier2014.html.

6Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58:308–312.

7Bristow RE, Hodeib M, Smith A, et al. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Am J ObstetGynecol. 2013;209:581.e1–581.e8.

8Partridge EE, Greenlee RT, Riley TL, et al. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the Prostate, Lung, Colorectal, and Ovarian Screening Trial. Obstet Gynecol. 2013;121:25–31.

9Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–46.